tbuckley/cabot-search huggingface dataset:
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results
Authors: Jorge E Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C Heinrich, Timothy P Hughes, Jeroen J W M Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Meng Cao, Matthias Hoch, Michael J Mauro
Journal: Leukemia (2025)

Data from in vitro and animal studies suggest that asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), synergizes with adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) to prevent emergence of and overcome resistance. Combination therapy may provide new treatment options for patients with chronic myeloid leukemia (CML) with suboptimal responses to ATP-competitive TKI monotherapy. Preliminary analysis of asciminib combined with nilotinib, imatinib, or dasatinib in a phase 1 dose-escalation study suggested promising efficacy and safety for patients with CML in chronic phase or accelerated phase treated with prior ATP-competitive TKIs; herein, we present final results from the 3 combination therapy arms. Asciminib, in combination with ATP-competitive TKIs, demonstrated rapid efficacy offset by a decreased tolerability compared with asciminib monotherapy. Based on these safety, tolerability, and preliminary efficacy results, asciminib 40 mg twice daily (BID) plus nilotinib 300 mg BID, asciminib 40 or 60 mg once daily (QD) plus imatinib 400 mg QD, and asciminib 80 mg QD plus dasatinib 100 mg QD were identified as recommended doses for expansion. The maximum tolerated dose was reached at asciminib 60 mg QD plus imatinib 400 mg QD and was not reached with asciminib plus nilotinib or dasatinib.
Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. <i>European Journal of Heart Failure</i> expert consensus document
Authors: Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler
Journal: European Journal of Heart Failure (2025)
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis’
Authors: Paschalis Karakasis, Eleftheria Lefkou, Konstantinos Pamporis, Stephane Heymans, Gerasimos Filippatos, Nikolaos Fragakis
Journal: European Journal of Heart Failure (2025)
Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L)
Authors: Akira Hamada, Junichi Soh, Akito Hata, Kiyoshi Nakamatsu, Mototsugu Shimokawa, Yasushi Yatabe, Jun Suzuki, Masahiro Tsuboi, Hidehito Horinouchi, Yuichi Sakairi, Masayuki Tanahashi, Shinichi Toyooka, Morihito Okada, Natusmi Matsuura, Hisayuki Shigematsu, Yasumasa Nishimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Tetsuya Mitsudomi
Journal: Journal of Thoracic Oncology (2025)
Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression
Authors: Cuilan Liu, Hengwei Du, Guoxing Yu, Jingjing Qi, Hongliang Dong, Ruiqi Hu, Fei Wang, Bingjie Cui, Weiwei Chen, Qian Zhang, Chen Li, Ran Gao, Clemens A. Schmitt, Jiong Deng, Yong Yu, Jing Du
Journal: Cancer Research (2025)

Abstract Chronic psychological stress is often associated with manifestations of malignant diseases. Identification of modulators regulating the interaction between stress and tumorigenesis could provide potential strategies to ameliorate cancer progression. Here, we observed that chronic stress markedly promoted lung cancer progression. Analysis of the landscape of lncRNA expression indicated that lncRNA HIF1A-AS3 was upregulated in the stressed group and in lung cancer specimens compared to normal tissues. HIF1A-AS3 promoted proliferation and invasion of lung cancer cells both in vitro and in vivo. Mechanistically, HIF1A-AS3 translationally activated HIF-1α via direct interaction with YBX1, stimulating downstream signaling cascades. HIF-1α inversely stimulated HIF1A-AS3 transcription by directly binding to its promoter region. Investigation of the immune microenvironment revealed that macrophage depletion could efficiently abolish the tumor promoting effects of chronic stress. Both chronic stress and HIF1A-AS3 overexpression induced M2-like macrophage polarization in tumor tissues in mice. Conditioned medium from HIF1A-AS3 overexpressing lung cancer cells enhanced the mobility and phagocytic activity of human and murine macrophages. Targeting HIF1A-AS3/HIF-1α signaling, which was aberrantly upregulated in human lung cancer specimens and predictive of poor prognosis, counteracted chronic stress-induced lung cancer progression in vivo. In conclusion, the HIF1A-AS3/HIF-1α positive feedback loop mediates chronic stress-induced lung cancer growth through functional reprogramming of tumor-associated macrophages, suggesting that this axis may serve as a promising diagnostic and therapeutic target for patients with lung cancer suffering from psychological stress.
Hotspots of escape: Oxidative niches prime tumor cell dissemination
Authors: Mario Palma, Marie Sabatier, Jessalyn M. Ubellacker
Journal: Cancer Research (2025)

Abstract The balance between reactive oxygen species (ROS) and antioxidant defenses plays a critical role in tumor development, progression, and response to therapy. However, the detection of ROS in vivo remains technically challenging. In a recent Nature Cell Biology publication, Ueda and colleagues developed a tool to help address this: T-AP1, a tumor-targeted probe that tracks extracellular H2O2 and allows for detection of ROS in vivo. The authors used T-AP1 to identify H2O2-rich zones within tumors, offering new insights into the spatial dynamics of oxidative stress in the tumor microenvironment. The authors show that tumor budding acts as a defense mechanism against oxidative stress in H2O2-rich regions established by neutrophils. Cancer cells exposed to H2O2 activate p38-MYC and contribute to a partial epithelial-mesenchymal transition that facilitates their physical escape from H2O2-rich regions. This defense mechanism is absent in tumors with NRF2 hyperactivation and in normal epithelial cells. This work further emphasizes the need for additional studies to clarify how ROS affects each stage of metastasis across different cancer types, and points to the potential of T-AP1 to be used as a novel tool to reveal distinct redox dynamics at each step.
Association of Clonal Hematopoiesis of Indeterminate Potential with Cardiovascular Events in Patients with CKD
Authors: Yang Pan, Caitlyn Vlasschaert, Varun Rao, Elvis A. Akwo, James E. Hixson, Mesbah Uddin, Zhi Yu, Do-Kyun Kim, Alexander Bick, Bryan Kestenbaum, Michael Chong, Guillaume Paré, Michael Rauh, Adeera Levin, James P. Lash, Manjula Kurella Tamura, Debbie L Cohen, Jiang He, Lee Hamm, Rajat Deo, Zeenat Bhat, Panduranga Rao, Dawei Xie, Pradeep Natarajan, Tanika N. Kelly, Cassianne Robinson-Cohen, Matthew B. Lanktree
Journal: Journal of the American Society of Nephrology (2025)

Background: Patients with CKD are at higher risk of cardiovascular disease. Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular disease in the general population, with a causal role observed in animal models. In the general population, the effect of CHIP is greater for somatic mutations in pre-defined CHIP driver genes other than DNMT3A (referred to as non- DNMT3A CHIP). We sought to assess the prospective association between CHIP and cardiovascular events in patients with CKD. Methods: CHIP was measured by high-depth targeted sequencing. The primary analysis tested the association of somatic mutations in non- DNMT3A CHIP driver genes with a composite cardiovascular disease endpoint of myocardial infarction, stroke, congestive heart failure, and peripheral artery disease in 5,043 patients with CKD in four prospective cohorts. Sensitivity analyses examined the effect of CHIP subtypes, race, baseline comorbidities, APOL1 risk alleles, and IL6R p.Asp358Ala genotype. Results: At baseline, patients had a mean age of 66 ± 12 years and eGFR of 43 ± 18 ml/min/1.73m 2 . CHIP was present in 24% of patients, with 13% of all patients carrying acquired non- DNMT3A mutations. Non- DNMT3A CHIP was associated with a 36% higher risk of the composite cardiovascular endpoint [95% confidence interval (CI), 6% - 76%]. Among composite components, non- DNMT3A CHIP was associated with a higher risk of stroke (HR 1.65; 95% CI 1.10 – 2.47). Baseline eGFR, diabetes status, or race did not alter the association of non- DNMT3A CHIP with cardiovascular risk. Those without genetically reduced interleukin-6 signaling (non-carriers of IL6R p.Asp358Ala) had worse disease (HR 1.46; 95% CI 1.17– 1.83, P subgroup difference = 0.05). Conclusions: In patients with CKD, non- DNMT3A CHIP was associated with cardiovascular disease with an effect size similar to that reported in the general population.
Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges
Authors: Tao Zhang, Zijun Ouyang, Yueran Zhang, Haiyan Sun, Lingdong Kong, Qiang Xu, Jiao Qu, Yang Sun
Journal: Medicinal Research Reviews (2025)

ABSTRACT In recent decades, the potentiality of marine natural products (MNPs) in the medical field has been increasingly recognized. Natural compounds derived from marine microorganisms, algae, and invertebrates have shown significant promise for treating inflammation‐related diseases. In this review, we cover the three primary sources of MNPs and their diverse and unique chemical structures and bioactivities. This review aims to summarize the progress of MNPs in combating inflammation‐related diseases. Moreover, we cover the functions and mechanisms of MNPs in diseases, highlighting their functions in regulating inflammatory signaling pathways, cellular stress responses, and gut microbiota, among others. Meanwhile, we focus on key technologies and scientific methods to address the current limitations and challenges in MNPs.
How does antifungal resistance vary in Candida (Candidozyma) auris and its clades? Quantitative and qualitative analyses and their clinical implications
Authors: Kássia Jéssica Galdino da Silva, Fabíola Lucini, Renato Augusto Corrêa Dos Santos, Daniel Assis Santos, Jacques F Meis, Marcia de Souza Carvalho Melhem, Nalu Teixeira de Aguiar Peres, Rafael Wesley Bastos, Luana Rossato
Journal: Clinical Microbiology and Infection (2025)
Author Correction: AI-guided precision parenteral nutrition for neonatal intensive care units
Authors: Thanaphong Phongpreecha, Marc Ghanem, Jonathan D Reiss, Tomiko T Oskotsky, Samson J Mataraso, Davide De Francesco, S Momsen Reincke, Camilo Espinosa, Philip Chung, Taryn Ng, Jean M Costello, Jennifer A Sequoia, Sheila Razdan, Feng Xie, Eloise Berson, Yeasul Kim, David Seong, May Y Szeto, Faith Myers, Hannah Gu, John Feister, Courtney P Verscaj, Laura A Rose, Lucas W Y Sin, Boris Oskotsky, Jacquelyn Roger, Chi-Hung Shu, Sayane Shome, Liu K Yang, Yuqi Tan, Steven Levitte, Ronald J Wong, Brice Gaudillière, Martin S Angst, Thomas J Montine, John A Kerner, Roberta L Keller, Gary M Shaw, Karl G Sylvester, Janene Fuerch, Valerie Chock, Shabnam Gaskari, David K Stevenson, Marina Sirota, Lawrence S Prince, Nima Aghaeepour
Journal: Nature Medicine (2025)
Author Correction: Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial
Authors: Ye Zhang, Jianjun Li, Yewei Xie, Dan Wu, Jason Ong, Gifty Marley, Adeeba Kamarulzaman, Haidong Lu, Fei Zou, Jennifer S Smith, Joseph D Tucker, Gengfeng Fu, Weiming Tang
Journal: Nature Medicine (2025)
Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD
Authors: Caitlyn Vlasschaert, Yang Pan, Jianchun Chen, Elvis Akwo, Varun Rao, James E. Hixson, Michael Chong, Md Mesbah Uddin, Zhi Yu, Mengdi Jiang, Fenfen Peng, Shirong Cao, Yinqiu Wang, Do-Kyun Kim, Adriana M. Hung, Jing He, Manjula Kurella Tamura, Debbie L. Cohen, Jiang He, Changwei Li, Zeenat Bhat, Panduranga Rao, Dawei Xie, Alexander G. Bick, Bryan Kestenbaum, Guillaume Paré, Michael J. Rauh, Adeera Levin, Pradeep Natarajan, James P. Lash, Ming-Zhi Zhang, Raymond C. Harris, Cassianne Robinson-Cohen, Matthew B. Lanktree, Tanika N. Kelly
Journal: Journal of the American Society of Nephrology (2025)

Background: Clonal hematopoiesis of indeterminate potential (CHIP) is a common inflammatory condition of aging that causes myriad end-organ damage. CHIP has been associated with incident AKI and kidney function decline in the general population, particularly mutations in CHIP genes other than DNMT3A (termed non- DNMT3A CHIP). Prior studies of CHIP in individuals with CKD had limited sample sizes and conflicting findings. Methods: We examined CHIP and CKD progression in four CKD cohorts (N = 5,654): the Chronic Renal Insufficiency Cohort (CRIC), the African American Study of Kidney Disease (AASK), individuals with CKD from the BioVU biorepository, and the Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT).Primary outcomes were incident CKD progression (50% eGFR decline or kidney failure), and eGFR slope over time. In addition, kidney function and pathology were assessed in a Tet2 -CHIP mouse model of CKD induced by dietary adenine. Results: Across all cohorts the average age was 66 ± 11 years, with an average baseline eGFR of 43 ± 15 ml/min/1.73m 2 , and 24% had CHIP. After meta-analysis, non- DNMT3A CHIP was associated with a 64% higher relative risk of incident CKD progression (hazard ratio [HR] 1.64; 95% confidence interval [CI], 1.00-2.68), with the strongest effect observed in individuals with baseline eGFR 30–60 ml/min/1.73m 2 (HR 1.85, 95% CI: 1.18–2.90). Non- DNMT3A CHIP carriers also exhibited a faster eGFR decline (β, -0.62 ± 0.28 ml/min/1.73m 2 per year; P = 0.03). In a dietary adenine mouse model of CKD, Tet2 -CHIP was associated with lower GFR as well as greater kidney inflammation, tubular injury, and tubulointerstitial fibrosis. Conclusions: Non- DNMT3A CHIP was associated with CKD progression among individuals with CKD. Further, Tet2-CHIP mouse models support a causal role in kidney injury.
Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission
Authors: Madeleine F Jennewein, Michael D Schultz, Samuel Beaver, Peter Battisti, Julie Bakken, Derek Hanson, Jobaida Akther, Fen Zhou, Raodoh Mohamath, Jasneet Singh, Noah Cross, Darshan N Kasal, Matthew R Ykema, Sierra Reed, Davies Kalange, Isabella R Cheatwood, Jennifer L Tipper, Jeremy B Foote, R Glenn King, Aaron Silva-Sanchez, Kevin S Harrod, Davide Botta, Alana Gerhardt, Corey Casper, Troy D Randall, Frances E Lund, Emily A Voigt
Journal: Molecular Therapy (2025)
Author Correction: Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds
Authors: Xi Tian, Michael E Werner, Kyle C Roche, Ariel D Hanson, Henry P Foote, Stephanie K Yu, Samuel B Warner, Jonathan A Copp, Haydee Lara, Eliane L Wauthier, Joseph M Caster, Laura E Herring, Longzhen Zhang, Joel E Tepper, David S Hsu, Tian Zhang, Lola M Reid, Andrew Z Wang
Journal: Nature Biomedical Engineering (2025)
Glucose-Triggered NO-Evolving Coating Bestows Orthopedic Implants with Enhanced Anti-Bacteria and Angiectasis for Safeguarding Diabetic Osseointegration
Authors: Hongxing Shi, Hao Yang, Chao Wu, Song Wang, Shuai He, Lin Chen, Yau Kei Chan, Shuangquan Lai, Kunneng Liang, Yi Deng
Journal: Biomaterials (2025)
Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes
Authors: Diamantis I. Tsilimigras, Selamawit Woldesenbet, Brittany L. Waterman, Anne M. Noonan, Timothy M. Pawlik
Journal: Journal of the National Comprehensive Cancer Network (2025)

Background: Evaluation of the quality of care delivered to patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) has been limited. We sought to examine trends and racial/ethnic disparities in quality of care among patients with mPDAC as well as the impact on outcomes using a novel and easily applied quality metric. Methods: Medicare beneficiaries diagnosed with mPDAC between 2005 and 2019 were identified using SEER-Medicare data. Achievement of a quality score based on 3 criteria was assessed: (1) cancer-specific survival (CSS) &gt;12 months, (2) receipt of systemic therapy, and (3) utilization of hospice/palliative care services. We examined factors associated with achieving the quality score, including race/ethnicity, social vulnerability index (SVI), and year of treatment. The impact of the quality score on CSS was also analyzed. Results: Among 14,147 patients with mPDAC, 62.2% (n=8,794) received systemic therapy, 83.3% (n=11,791) utilized palliative care/hospice services, and 13.7% (n=1,933) had CSS &gt;12 months after diagnosis. Achievement of at least one quality criterion increased over time (from 84.5% in 2005 to 97.0% in 2019; P &lt;.001). Multivariable analysis showed that a high overall SVI (odds ratio [OR], 0.70; 95% CI, 0.54–0.91) was independently associated with lower odds of meeting at least one quality criterion. This effect was mainly driven by the SVI subthemes of high socioeconomic status (OR, 0.66; 95% CI, 0.48–0.90) and high racial/ethnic minority status (OR, 0.75; 95% CI, 0.60–0.93). Achievement of quality score ≥1 (excluding CSS criterion) was associated with improved overall survival (1-year CSS, 14.5% vs 3.2%; P &lt;.001). Conclusions: Approximately 9 in 10 patients with mPDAC achieved at least one of the quality score criteria, though racial/ethnic minority patients and socially vulnerable populations had lower achievement. Lower quality score achievement was associated with poorer long-term survival. These findings highlight the need for targeted interventions to meet quality metrics for all patients with mPDAC to mitigate disparities in end-of-life care.
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Authors: J. Sybil Biermann, Angela Hirbe, Shivani Ahlawat, Nicholas M. Bernthal, Odion Binitie, Sarah Boles, Brian Brigman, Alexandra K. Callan, Cara Cipriano, Lee D. Cranmer, Jessica Davis, Eric Donnelly, Michael Ferguson, Ann Graham, John Groundland, Matthew Hess, Susan M. Hiniker, Margo L. Hoover-Regan, Jason L. Hornick, Brandon Jonard, Joseph B. Kuechle, Dieter Lindskog, Joel L. Mayerson, Sean V. McGarry, Carol D. Morris, Daniel Olson, Peter S. Rose, Victor M. Santana, Robert L. Satcher, Herbert Schwartz, Rebecca M. Shulman, Steven W. Thorpe, Breelyn A. Wilky, Rosanna L. Wustrack, Janet Yoon, Lisa E. Hang, Frankie Jones, Nicholas Sansone, Megan Lyons
Journal: Journal of the National Comprehensive Cancer Network (2025)

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Authors: Timothy Gilligan, Daniel W. Lin, Nabil Adra, Aditya Bagrodia, Darren R. Feldman, Kosj Yamoah, Rahul Aggarwal, Thenappan Chandrasekar, Daniel Costa, Alexandra Drakaki, Scott Eggener, Hamid Emamekhoo, Daniel M. Geynisman, Laura Graham, Peter Humphrey, Harshraj Leuva, Ellis G. Levine, Amy Luckenbaugh, Benjamin L. Maughan, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Zachery Reichert, Jean-Claude Rwigema, Philip Saylor, Ankeet Shah, Sumit Shah, Nirmish Singla, Kanishka Sircar, David VanderWeele, Ali Zhumkhawala, Sarah Montgomery, Bailee Sliker
Journal: Journal of the National Comprehensive Cancer Network (2025)

The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.
Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer
Authors: Benjamin A. Lerner, Samir Gupta, Carol A. Burke, Sonia Kupfer, Bryson W. Katona, William M. Grady, Jewel J. Samadder, Matthew B. Yurgelun, Kaitlyn J. Kelly, Mariana Moreno Prats, Nora Joseph, Gregory E. Idos, Benjamin J. Swanson, AnnMarie Kieber-Emmons, Jennifer M. Weiss, Xavier Llor
Journal: Journal of the National Comprehensive Cancer Network (2025)

Gastric cancer is a significant global health concern, with CDH1 -associated gastric cancer representing a small but important subset of cases. Historically, individuals with CDH1 pathogenic germline variants were advised to undergo prophylactic total gastrectomy due to the high reported risk of gastric cancer and the limited sensitivity of upper endoscopy in detecting signet ring cell carcinoma (SRCC). However, emerging data suggest that the cumulative lifetime risk of advanced gastric cancer among CDH1 germline pathogenic variant carriers is lower than previously thought, and early-stage SRCC detected on endoscopy does not necessarily indicate imminent—or even eventual—progression to advanced cancer. The near-universal presence of T1a SRCC in gastrectomy specimens from asymptomatic CDH1 pathogenic variant carriers calls into question the reflexive recommendation for gastrectomy, including upon detection of SRCC during surveillance. Furthermore, the morbidity and quality-of-life impact associated with total gastrectomy require careful consideration. Active endoscopic surveillance has shown promise as an alternative management strategy for gastrectomy in patients lacking indicators of &gt;T1a SRCC, though current data are limited by short follow-up periods and selection bias. This review synthesizes recent findings on the natural history of CDH1 -associated gastric cancer and evaluates the risks and benefits of gastrectomy versus active endoscopic surveillance, with the goal of helping clinicians provide personalized and evidence-based recommendations for patients with CDH1 pathogenic variants.
Primary Mitral Regurgitation, Surgery in the Transcatheter Era: When the neighbourhood becomes noisy: A State of Art Review
Authors: Edoardo Zancanaro, Julia Grapsa, Karl Patrick Kresoja, Guido Ascione, Kabir Sethi, Sebastian Rosch, Davide Carino, Daniel Sebastian Dohle, Michele Di Mauro, Ralph Stephan von Bardeleben, Hendrik Treede, Philipp Lurz, Roberto Lorusso
Journal:  (2025)

Primary mitral regurgitation is a valvular heart disorder that found to be treated with surgery that has been the gold standard for decades with different techniques to approach this pathology. In the last decade, Transcatheter Edge-to-Edge Repair emerged as a valid option for this type of pathology, in case of surgical unsuitability. Others device emerged as well leaving less remark compared with Transcatheter Edge-to-Edge Repair. The article analyse the old and new frontiers as well as the controversies of this phenotype.